Novartis Withdraws Prexige In Australia Ahead Of FDA Decision Due To Deaths
This article was originally published in The Pink Sheet Daily
Executive Summary
Withdrawal of the COX-2 inhibitor in Australia following two deaths from liver injury is likely to impact the outcome of FDA’s review.
You may also be interested in...
Ouch, Canada! Prexige Withdrawn From Yet Another Market
Ottawa withdraws marketing authorization for Novartis’ troubled anti-inflammatory drug due to the potential for serious liver damage.
Ouch, Canada! Prexige Withdrawn From Yet Another Market
Ottawa withdraws marketing authorization for Novartis’ troubled anti-inflammatory drug due to the potential for serious liver damage.
No Big Surprise For Novartis: Prexige Is “Not Approvable” At FDA
Firm now plans to discuss path forward, which may include additional trials of the COX-2 inhibitor, with FDA, Novartis tells "The Pink Sheet" DAILY.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: